Point-of-care testing for COVID-19 using SHERLOCK diagnostics
Julia Joung(Broad Institute), Feng Zhang(Southwest Jiaotong University), Omar O. Abudayyeh(Brigham and Women's Hospital), Nam‐Gyun Kim(Pukyong National University), Michael Segel(Broad Institute), Makoto Saito(Broad Institute), Alim Ladha(Broad Institute), Alexander L. Greninger(University of Washington), Jonathan S. Gootenberg(Brigham and Women's Hospital), Xu G. Yu(Massachusetts General Hospital), Robert Bruneau(University of Washington), Jonathan Li(Brigham and Women's Hospital), Keith R. Jerome(University of Washington), Mee-li W. Huang(University of Washington), Bruce D. Walker(Howard Hughes Medical Institute)
Cited by 336
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Cervicovaginal Bacteria Are a Major Modulator of Host Inflammatory Responses in the Female Genital Tract
|Immunity|2015|824
Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing
|New England Journal of Medicine|2020|801
Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA
|Nature Biomedical Engineering|2020|659